This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
In a quiet office in an industrial park in Jerusalem, an Israeli woman in a white coat slowly binds a black coil to the surface of a metal dome. She is creating the insides of a helmet that may help treat millions of people with clinical depression.
The machine is made by Brainsway®, a Tel Aviv-listed medical devices company, which has a market capitalisation of about US$260 million (S$355 million). It has pioneered a treatment known as “deep transcranial magnetic stimulation”, using a helmet to aim magnetic fields at a patient’s brain tissues. This can target the reward system in the brain, helping to counter and relieve symptoms of depression.
Read more here.